School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.
Health Technol Assess. 2014 Jan;18(1):1-74. doi: 10.3310/hta18010.
Severe mental illnesses (SMIs), such as schizophrenia and bipolar disorder, persist over time and can cause extensive disability leading to impairments in social and occupational functioning. People with SMI have higher morbidity and mortality due to physical illness than the general population and may be more likely to engage in high-risk sexual behaviour (e.g. unprotected intercourse, having multiple partners, involvement in the sex trade and illicit drug use), putting them at risk of poorer sexual health outcomes including sexually transmitted infections. Sexual health promotion interventions, developed and implemented for people with SMI, may improve participants' knowledge, attitudes, beliefs or behavioural practices and could lead to a reduction in risky sexual behaviour.
To evaluate the effectiveness of sexual health interventions for people with SMI compared with usual care and their applicability to the UK NHS setting.
Thirteen electronic databases were searched from inception to December 2012. All controlled trials (randomised or non-randomised) that met the following criteria were included: any sexual health promotion intervention or combination of interventions intended to change the knowledge, attitudes, beliefs, behaviours or practices of individuals with SMI (defined as adults aged ≥ 18 years who have received a diagnosis of schizophrenia or bipolar disorder) living in the community.
A systematic review of the clinical evidence was undertaken following recommended guidelines. Data were tabulated and discussed in a narrative review.
Thirteen randomised controlled studies met the inclusion criteria. The methodological quality of the included studies varied considerably, with only a minority of studies (n = 2) being considered as having very few methodological limitations. Despite wide variations in the study populations, interventions, comparators and outcomes, four studies showed significant improvements in all measured sexual risk behaviour outcomes (e.g. human immunodeficiency virus knowledge and behaviour change) in the intervention groups compared with the control groups. In contrast, four studies found significant improvements in the intervention groups for some outcomes only and three studies found significant improvements in certain subgroups only, based on either gender or ethnicity. Finally, two studies reported no significant differences in any sexual risk behaviour outcomes between the intervention and control groups. Moreover, positive findings were not consistently sustained at follow-up in many studies.
Little detail was provided in the studies regarding the content of interventions, how they were delivered and by whom, making replication or generalisability difficult.
Owing to the large between-study variability (especially in the populations, interventions, comparators and reported outcomes) and mixed results, there is insufficient evidence to fully support or reject the identified sexual health interventions for people with SMI. In addition, there are considerable uncertainties around the generalisability of these findings to the UK setting. Further research recommendations include well-designed, UK-based trials of sexual health interventions for people with SMI as well as training and support for staff implementing sexual health interventions.
PROSPERO number CRD42013003674.
The National Institute for Health Research Health Technology Assessment Programme.
严重精神疾病(SMI),如精神分裂症和双相情感障碍,会随着时间的推移而持续存在,并导致广泛的残疾,从而影响社会和职业功能。与一般人群相比,患有 SMI 的人因身体疾病而导致更高的发病率和死亡率,并且可能更倾向于从事高风险的性行为(例如无保护的性行为、多个伴侣、参与性交易和非法药物使用),从而使他们面临更差的性健康结局,包括性传播感染。针对 SMI 患者开发和实施的性健康促进干预措施,可能会提高参与者的知识、态度、信念或行为实践,并可能导致减少高风险性行为。
评估与常规护理相比,针对 SMI 患者的性健康干预措施的有效性,以及它们在英国国民保健制度环境中的适用性。
从创建到 2012 年 12 月,对 13 个电子数据库进行了搜索。符合以下标准的所有对照试验(随机或非随机)均被纳入:任何旨在改变 SMI 个体(定义为年龄≥18 岁的成年人,已被诊断为精神分裂症或双相情感障碍)的知识、态度、信念、行为或实践的性健康促进干预或干预组合,生活在社区中。
按照建议的指南进行了临床证据的系统评价。数据以叙述性综述的形式进行了制表和讨论。
有 13 项随机对照研究符合纳入标准。纳入研究的方法学质量差异很大,只有少数研究(n=2)被认为只有极少数方法学局限性。尽管研究人群、干预措施、对照组和结局存在广泛差异,但四项研究显示,干预组在所有测量的性风险行为结局(例如艾滋病毒知识和行为改变)方面均有显著改善,而对照组则没有。相比之下,四项研究发现干预组仅在某些结局方面有显著改善,三项研究仅发现某些亚组有显著改善,这取决于性别或种族。最后,两项研究报告干预组和对照组之间在任何性风险行为结局方面均无显著差异。此外,许多研究在随访中并未持续显示出阳性结果。
研究中对干预措施的内容、如何实施以及由谁实施提供的细节很少,这使得复制或推广变得困难。
由于研究之间存在很大的变异性(特别是在人群、干预措施、对照组和报告的结局方面)以及混合结果,因此没有足够的证据完全支持或拒绝针对 SMI 患者的已确定的性健康干预措施。此外,这些发现对英国环境的推广性存在很大的不确定性。进一步的研究建议包括针对 SMI 患者的性健康干预措施进行精心设计的、基于英国的试验,以及对实施性健康干预措施的工作人员进行培训和支持。
PROSPERO 编号 CRD42013003674。
英国国家卫生研究所健康技术评估计划。